2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Cyclophosphamide
910
Carboplatin
788
pembrolizumab
747
Paclitaxel
744
Bevacizumab
716
Cisplatin
709
Gemcitabine
621
Docetaxel
584
Rituximab
558
Radiotherapy
548
Dexamethasone
511
Nivolumab
491
Doxorubicin
445
Fluorouracil
392
Capecitabine
382
Etoposide
358
Pemetrexed
339
Cytarabine
335
Oxaliplatin
335
Lenalidomide
328
Prednisone
327
Erlotinib Hydrochloride
323
fludarabine phosphate
316
Trastuzumab
305
Leucovorin
299
fludarabine
296
Vincristine
288
Bortezomib
284
Filgrastim
284
Cetuximab
277
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
pralsetinib
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts